---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-25-000006"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T00:52:32.280947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novavax reports Q4 revenue $88M, net loss $81M; transitions COVID vaccine to Sanofi; guides 2025 adj revenue $300-350M

## Summary
- Q4 2024 revenue $88M (vs $291M YoY); full year $682M (vs $984M). Product sales $50M vs $251M.
- Net loss narrowed to $81M in Q4 (vs $178M); full year loss $187M (vs $545M). Cash $938M at Dec 31, 2024.
- Transitioned Nuvaxovid commercial lead to Sanofi for 2025-2026 season. BLA target action date April 2025; $175M milestone upon approval.
- Sold Czech facility to Novo Nordisk for $200M; gain of $52M, annual cost savings ~$80M.
- 2025 guidance: combined R&D+SG&A $475-525M; adjusted licensing/royalties/other revenue $300-350M.

## SEC filing metadata
- accession: 0001000694-25-000006
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000006/0001000694-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000006/nvax-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-25-000006
- JSON: https://secwatch.observer/filing/0001000694-25-000006.json
- Plain text: https://secwatch.observer/filing/0001000694-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.